J&J adds to COVID-19 vaccine armory with 66% efficacy in global trial

The first single-shot vaccine, made by Janssen, appears 66% effective overall at preventing moderate to severe COVID-19. It was more protective against severe symptoms, 85%. (AP)
Short Url
Updated 29 January 2021
Follow

J&J adds to COVID-19 vaccine armory with 66% efficacy in global trial

  • J&J will seek emergency use authorization in U.S. next week
  • The pharmaceutical giant has said it plans to deliver 1 billion doses in 2021

LONDON: Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.
A high bar has been set by two authorized vaccines from Pfizer/BioNTech and Moderna, which were around 95% effective in preventing symptomatic illness in pivotal trials when given in two doses.
Those trials, however, were conducted mainly in the United States and before new variants emerged.
The top US infectious disease specialist Anthony Fauci said the variations in effectiveness around the world underlined the need to vaccinate as many people as quickly as possible to prevent new variants from emerging.
“It’s really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve,” Fauci said.
J&J’s main goal was the prevention of moderate to severe COVID-19, and the vaccine was 85% effective in stopping severe disease and preventing hospitalization across all geographies and against multiple variants 28 days after immunization.
That “will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19,” Paul Stoffels, J&J’s chief scientific officer, said of the results, which were based on 468 symptomatic cases.
J&J plans to seek emergency use authorization from the US Food and Drug Administration next week. It has said it plans to deliver 1 billion doses in 2021 and will produce the vaccine in the United States, Europe, South Africa and India.
Public health officials are counting on the J&J vaccine to increase much-needed supply and simplify immunization in the United States, which has a deal to buy 100 million doses of J&J’s vaccine and an option for an additional 200 million.
J&J said the vaccine would be ready immediately upon emergency approval, but Stoffels declined to say how many doses.
“Right now, any protection and additional vaccine is great. The key is not only overall efficacy but specifically efficacy against severe disease, hospitalization, and death,” Walid Gellad, a health policy associate professor at the University of Pittsburgh, said.
Michael Breen, Director of Infectious Diseases and Ophthalmology at research firm GlobalData said “Most countries are still desperate to get their hands on doses, regardless of whether or not the vaccine is considered highly effective. Moderately effective will do just fine for now.”
None of the vaccine recipients in the J&J trial died from COVID-19, compared with 5 in the placebo group, the National Institutes of Health said. Three deaths in the vaccine group overall, but none were determined to be from the virus. That compares with 16 deaths overall in the placebo arm, it added.
Unlike the Pfizer and Moderna vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world where transportation and cold storage are an issue.

SOUTH AFRICAN VARIANT
Several studies have emerged this month showing that a South African variant has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.
“What we are learning is there is different efficacy in different parts of the world,” Stoffels told Reuters.
In a sub-study of 6,000 volunteers in South Africa, Stoffels said, the J&J vaccine was 89% effective at preventing severe disease. In the South Africa portion of the trial, 95% of cases were infections with the South African variant.
“I am overwhelmed by the fact that this vaccine protected against severe disease even in South Africa,” said Glenda Gray, the joint lead investigator of the South African vaccine trial.
Gray, who is the chief executive of the South African Medical Research Council, said this is by far the best vaccine for South Africa to fight the mutant strain and can prevent a large number of hospitalizations and deaths.
A mid-stage trial of a Novovax coronavirus vaccine in South Africa also showed lower efficacy, proving to be 60% effective among volunteers who didn’t have HIV. In a separate, late-stage trial in Britain it was 89.3% effective.
In the J&J trial, which was conducted in eight countries, 44% of participants were from the United States, 41% from Central and South America and 15% from South Africa. Slightly more than a third of the volunteers were over 60.
J&J’s vaccine uses a common cold virus to introduce coronavirus proteins into cells in the body and trigger an immune response, whereas the Pfizer/BioNTech and Moderna vaccines use a new technology called messenger RNA (mRNA).


Millions of Afghans face hunger as aid cuts deepen a humanitarian crisis

Updated 9 sec ago
Follow

Millions of Afghans face hunger as aid cuts deepen a humanitarian crisis

  • Millions of Afghans are struggling as international aid cuts sever a lifeline many relied on for food and heating
  • The International Committee for the Red Cross says nearly half the population needed aid in 2025
KABUL: For 10 hours a day, Rahimullah sells socks from his cart in eastern Kabul, earning about $4.5 to $6 per day. It’s a pittance, but it’s all he has to feed his family of five.
Rahimullah, who like many Afghans goes by only one name, is one of millions of Afghans who rely on humanitarian aid, both from the Afghan authorities and from international charity organizations, for survival. An estimated 22.9 million people — nearly half the population — required aid in 2025, the International Committee for the Red Cross said in an article on its website Monday.
But severe cuts in international aid — including the halting of US aid to programs such as food distribution run by the United Nations’ World Food Program — have severed this lifeline.
More than 17 million people in Afghanistan now face crisis levels of hunger in the winter, the World Food Program warned last week, 3 million more than were at risk more than a year ago.
The slashing in aid has come as Afghanistan is battered by a struggling economy, recurrent droughts, two deadly earthquakes and the mass influx of Afghan refugees expelled from countries such as Iran and Pakistan. The resulting multiple shocks have severely pressured resources, including of housing and food.
UN appeals for help
Tom Fletcher, the UN humanitarian chief, told the Security Council in mid-December that the situation was compounded by “overlapping shocks,” including the recent earthquakes and increasing restrictions on humanitarian aid access and staff.
While Fletcher said nearly 22 million Afghans will need UN assistance in 2026, his organization will focus on 3.9 million facing the most urgent need of lifesaving help due to reduced donor contributions.
Fletcher said this winter was “the first in years with almost no international food distribution.”
“As a result, only about 1 million of the most vulnerable people have received food assistance during the lean season in 2025,” compared to 5.6 million last year, he said.
The year has been devastating for UN humanitarian organizations, which have had to cut thousands of jobs and spending in the wake of aid cuts.
“We are grateful to all of you who have continued to support Afghanistan. But as we look toward 2026, we risk a further contraction of life-saving help — at a time when food insecurity, health needs, strain on basic services, and protection risks are all rising,” Fletcher said.
Returning refugees
The return of millions of refugees has added pressure on an already teetering system. Minister of Refugees and Repatriation Affairs Abdul Kabir said Sunday that 7.1 million Afghan refugees had returned to the country over the last four years, according to a statement on the ministry website.
Rahimullah, 29, was one of them. The former Afghan Army soldier fled to neighboring Pakistan after the Taliban seized power in 2021. He was deported back to Afghanistan two years later, and initially received aid in the form of cash as well as food.
“The assistance was helping me a lot,” he said. But without it, “now I don’t have enough money to live on. God forbid, if I were to face a serious illness or any other problem, it would be very difficult for me to handle because I don’t have any extra money for expenses.”
The massive influx of former refugees has also sent rents skyrocketing. Rahimullah’s landlord has nearly doubled the rent of his tiny two-room home, with walls made half of concrete and half of mud and a homemade mud stove for cooking. Instead of 4,500 afghanis (about $67), he now wants 8,000 afghanis (about $120) – a sum Rahimullah cannot afford. So he, his wife, daughter and two young sons will have to move next month. They don’t know where to.
Before the Taliban takeover, Rahimullah had a decent salary and his wife worked as a teacher. But the new government’s draconian restrictions on women and girls mean women are barred from nearly all jobs, and his wife is unemployed.
“Now the situation is such that even if we find money for flour, we don’t have it for oil, and even if we find it for oil, we can’t pay the rent. And then there is the extra electricity bill,” Rahimullah said.
Harsh winters compound the misery
In Afghanistan’s northern province of Badakhshan, Sherin Gul is desperate. In 2023, her family of 12 got supplies of flour, oil, rice, beans, pulses, salt and biscuits. It was a lifesaver.
But it only lasted six months. Now, there is nothing. Her husband is old and weak and cannot work, she said. With 10 children, seven girls and three boys between the ages of 7 and 27, the burden of providing for the family has fallen on her 23-year-old son – the only one old enough to work. But even he only finds occasional jobs.
“There are 12 of us … and one person working cannot cover the expenses,” she said. “We are in great trouble.”
Sometimes neighbors take pity on them and give them food. Often, they all go hungry.
“There have been times when we have nothing to eat at night, and my little children have fallen asleep without food,” Gul said. “I have only given them green tea and they have fallen asleep crying.”
Before the Taliban takeover, Gul worked as a cleaner, earning just about enough to feed her family. But the ban on women working has left her unemployed, and she said she developed a nervous disorder and is often sick.
Compounding their misery is the harsh cold of the northern Afghan winter, when snow halts construction work where her son can sometimes find jobs. And there is the added expense of firewood and charcoal.